EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study

Ziad Reguiai, Anne-Claire Fougerousse, Hervé Bachelez, Lisa Fredeau, Chloé Grolleau, Jean-David Bouaziz, Marie Jachiet, Thibault Mahevas, Nicole Jouan, Christelle Pruvost-Balland, Nathalie Sultan, Clotilde Fera und 5 weitere

Journal of the American Academy of Dermatology · 2026-09 · 95 (3) · 814-816

DOI: 10.1016/j.jaad.2026.05.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-09. Verfasst von Ziad Reguiai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infliximab is used off-label in moderate-to-severe hidradenitis suppurativa (HS).1,2 A subcutaneous (SC) formulation is now available for rheumatoid arthritis, inflammatory bowel disease, axial spondyloarthritis and psoriasis. As it is used off label in HS, data on switching from IV to SC infliximab are lacking. We conducted a retrospective multicenter study across 8 French dermatology centers. All HS patients switched from IV to SC infliximab between August 2021 and October 2025 were included. The decision to switch from IV to SC infliximab was made at the attending physician's discretion.

Schlagwörter

Stichwörter der Autor:innen

biologicshidradenitis suppurativainfliximab

Autor:innen und Institutionen

  • Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France.
  • Department of Dermatology, Military Teaching Hospital Bégin, Saint Mandé, France.
  • Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1342, Paris, France; Dermatology Department, APHP, Hôpital Saint-Louis, Paris, France.
  • Dermatology Department, APHP, Hôpital Saint-Louis, Paris, France; Department of Dermatology, Hôpital NOVO, Pontoise, France.
  • Dermatology Department, APHP, Hôpital Saint-Louis, Paris, France.
  • Dermatologic Office, Brest, France.

Zitieren

APA

Reguiai, Z., Fougerousse, A. C., Bachelez, H., Fredeau, L., Grolleau, C., Bouaziz, J. D., Jachiet, M., Mahevas, T., Jouan, N., Pruvost-Balland, C., Sultan, N., Fera, C., Brun, A., Libert, E. P., Fayad Kazour, A., Cassius, C., & HS-France group of the French Society of Dermatology and Reso-Verneuil (2026). Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study. Journal of the American Academy of Dermatology, 95(3), 814-816. https://doi.org/10.1016/j.jaad.2026.05.014

Vancouver

Reguiai Z, Fougerousse AC, Bachelez H, Fredeau L, Grolleau C, Bouaziz JD, et al. Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study. Journal of the American Academy of Dermatology. 2026;95(3):814-816. doi:10.1016/j.jaad.2026.05.014

BibTeX
@article{Reguiai2026,
  author = {Reguiai, Ziad and Fougerousse, Anne-Claire and Bachelez, Hervé and Fredeau, Lisa and Grolleau, Chloé and Bouaziz, Jean-David and Jachiet, Marie and Mahevas, Thibault and Jouan, Nicole and Pruvost-Balland, Christelle and Sultan, Nathalie and Fera, Clotilde and Brun, Aurore and Libert, Edgar-Pierre and Fayad Kazour, Alice and Cassius, Charles and HS-France group of the French Society of Dermatology and Reso-Verneuil, HS-France group of the French Society of Dermatology and Reso-Verneuil},
  title = {Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: A French multicenter retrospective study},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  volume = {95},
  number = {3},
  pages = {814--816},
  doi = {10.1016/j.jaad.2026.05.014}
}
Kostenlos starten →